| (Alkermes) ALKS 4230-001 / ARTISTRY-2 | A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors- ARTISTRY-2 (001) | Juergens, Dr Rosalyn | Open to recruitment | NCT03861793 |
| (Fusion) FPX-01-01 | A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumours | Juergens, Dr Rosalyn | Open to recruitment | NCT03746431 |
| (Merck) MK-1084-001 | A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors | Juergens, Dr Rosalyn | Open to recruitment | NCT05067283 |
| (Merck) MK-4830-001 | A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors | Hotte, Dr Sebastien | Open to recruitment | NCT03564691 |
| (SignalChem) SLC-391-101 | A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of the Safety and Pharmacokinetics of the AXL Inhibitor SLC-391 Administered Orally to Subjects with Solid Tumours | Hotte, Dr Sebastien | Open to recruitment | NCT03990454 |
Find a Trial
Contact Us